Involvement of hypoxia-inducible transcription factors in polycystic kidney disease

American Journal of Pathology

Volumn 170, Issue 3, 2007, Pages 830-842

  Bernhardt, Wanja Michael ^a   Wiesener, Michael Sean ^a,b   Weidemann, Alexander ^a   Schmitt, Roland ^c   Weichert, Wilko ^d   Lechler, Philipp ^a,b   Campean, Valentina ^a   Ong, Albert Chee Meng ^f   Willam, Carsten ^a   Gretz, Norbert ^e   Eckardt, Kai Uwe ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c FRANZ VOLHARD CLINIC   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PIMONIDAZOLE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ERYTHROPOIETIN; HEME OXYGENASE 1; HMOX1 PROTEIN, HUMAN; POLYCYSTIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY POLYCYSTIC DISEASE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL HYPOXIA; GENE EXPRESSION; IMMUNOBLOTTING; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION; GLUCOSE TRANSPORTER TYPE 1; HEME OXYGENASE-1; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY DISEASES; RATS; TRPP CATION CHANNELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247864018     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.060455     Document Type: Article

References (47)

1. Wilson PD: Polycystic kidney disease. N Engl J Med 2004, 350:151-164
2. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 1993, 329:332-342
3. Cowley Jr BD: Recent advances in understanding the pathogenesis of polycystic kidney disease: therapeutic implications. Drugs 2004, 64:1285-1294
4. Maïz HB, Abderrahim E, Zouaghi K: Anemia and end-stage renal disease in the developing world. Artif Organs 2002, 26:760-764
5. Abbott KC, Agodoa LY: Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002, 57:208-214
6. Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M: Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron 1985, 39:26-29
7. Eckardt KU, Mollmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, Scholz H, Keusch G, Buchholz B, Frei U, Kurtz A: Erythropoietin in polycystic kidneys. J Clin Invest 1989, 84:1160-1166
8. Bello-Reuss E, Holubec K, Rajaraman S: Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 2001, 60:37-45
9. Wei W, Popov V, Walocha JA, Wen J, Bello-Reuss E: Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int 2006, 70:1261-1268
10. Ohashi R, Kitamura H, Yamanaka N: Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. J Am Soc Nephrol 2000, 11:47-56
11. Ohashi R, Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N: Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol 2002, 13:1795-1805
12. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001, 12:1434-1447
13. Wiesener MS, Maxwell PH: HIF and oxygen sensing; as important to life as the air we breathe? Ann Med 2003, 35:183-190
14. Maxwell PH: Hypoxia-inducible factor as a physiological regulator. Exp Physiol 2005, 90:791-797
15. Haase VH: The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int 2006, 69:1302-1307
16. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU: Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002, 13:1721-1732
17. Rosenberger C, Griethe W, Gruber G, Wiesener M, Frei U, Bachmann S, Eckardt KU: Cellular responses to hypoxia after renal segmental infarction. Kidney Int 2003, 64:874-886
18. Rosenberger C, Heyman SN, Rosen S, Shina A, Goldfarb M, Griethe W, Frei U, Reinke P, Bachmann S, Eckardt KU: Up-regulation of HIF in experimental acute renal failure: evidence for a protective transcriptional response to hypoxia. Kidney Int 2005, 67:531-542
19. Schäfer K, Gretz N, Bader M, Oberbaumer I, Eckardt KU, Kriz W, Bachmann S: Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int 1994, 46:134-152
20. Kaspareit-Rittinghausen J, Deerberg F, Rapp KG, Wcislo A: A new rat model for polycystic kidney disease of humans. Transplant Proc 1990, 22:2582-2583
21. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU: Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003, 17:271-273
22. Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU: Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 2004, 18:1462-1464
23. Streets AJ, Newby LJ, O'Hare MJ, Bukanov NO, Ibraghimov-Beskrovnaya O, Ong AC: Functional analysis of PKD1 transgenic lines reveals a direct role for polycystin-1 in mediating cell-cell adhesion. J Am Soc Nephrol 2003, 14:1804-1815
24. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, Wood SM, Garter KC, Harris AL, Pugh CW, Ratcliffe PJ, Maxwell PH: Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998, 92:2260-2268
25. Heilig C, Zaloga C, Lee M, Zhao X, Riser B, Brosius F, Cortes P: Immunogold localization of high-affinity glucose transporter isoforms in normal rat kidney. Lab Invest 1995, 73:674-684
26. Simon M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W, Fuchs E: Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995, 268:F240-F250
27. Bernhardt WM, Schmitt R, Rosenberger C, Munchenhagen PM, Grone HJ, Frei U, Warnecke C, Bachmann S, Wiesener MS, Willam C, Eckardt KU: Expression of hypoxia-inducible transcription factors in developing human and rat kidneys. Kidney Int 2006, 69:114-122
28. Nordsmark M, Loncaster J, Quino-Parsons C, Chou SC, Ladekarl M, Havsteen H, Lindegaard JC, Davidson SE, Varia M, West C, Hunter R, Overgaard J, Raleigh JA: Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 2003, 67:35-44
29. Hellwig-Bürgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W: Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999, 94:1561-1567
30. D'Angelo G, Duplan E, Boyer N, Vigne P, Frelin C: Hypoxia upregulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem 2003, 278:38183-38187
31. Maxwell PH: The HIF pathway in cancer. Semin Cell Dev Biol 2005, 16:523-530
32. Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, Dewhirst MW: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005, 8:99-110
33. Macpherson GR, Figg WD: Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biol Ther 2004, 3:503-504
34. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004, 15:2115-2124
35. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F: Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93:2627-2636
36. Chauveau D, Duvic C, Chretien Y, Paraf F, Droz D, Melki P, Helenon O, Richard S, Grunfeld JP: Renal involvement in von Hippel-Lindau disease. Kidney Int 1996, 50:944-951
37. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275
38. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH: HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459-468
39. Rankin EB, Tomaszewski JE, Haase VH: Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 2006, 66:2576-2583
40. Esteban MA, Harten SK, Tran MG, Maxwell PH: Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J Am Soc Nephrol 2006, 17:1801-1806
41. Davenport JR, Yoder BK: An incredible decade for the primary cilium: a look at a once-forgotten organelle. Am J Physiol 2005, 289:F1159-F1169
42. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005, 16:46-51
43. Wahl PR, Serra AL, Le HM, Molle KD, Hall MN, Wuthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006, 21:598-604
44. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: From the cover: the mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006, 103:5466-5471
45. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12:122-127
46. Dekanty A, Lavista-Llanos S, Irisarri M, Oldham S, Wappner P: The insulin-PI3K/TOR pathway induces a HIF-dependent transcriptional response in Drosophila by promoting nuclear localization of HIF-alpha/Sima. J Cell Sci 2005, 118:5431-5441
47. Melillo G: HIF-1: a target for cancer, ischemia and inflammation - too good to be true? Cell Cycle 2004, 3:154-155